ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 50 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
In the past year ZEG had a positive cash flow from operations.
ZEG had positive earnings in each of the past 5 years.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.31%, ZEG is in the better half of the industry, outperforming 62.00% of the companies in the same industry.
The Return On Equity of ZEG (18.94%) is better than 70.00% of its industry peers.
With a decent Return On Invested Capital value of 14.10%, ZEG is doing good in the industry, outperforming 80.00% of the companies in the same industry.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 14.77%.
The last Return On Invested Capital (14.10%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROIC | 14.1% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
Looking at the Profit Margin, with a value of 14.14%, ZEG is in the better half of the industry, outperforming 66.00% of the companies in the same industry.
ZEG's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 24.05%, ZEG is in the better half of the industry, outperforming 68.00% of the companies in the same industry.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG has a better Gross Margin (82.36%) than 84.00% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
The number of shares outstanding for ZEG has been increased compared to 5 years ago.
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.92 indicates that ZEG is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZEG (4.92) is better than 78.00% of its industry peers.
The Debt to FCF ratio of ZEG is 3.46, which is a good value as it means it would take ZEG, 3.46 years of fcf income to pay off all of its debts.
ZEG's Debt to FCF ratio of 3.46 is fine compared to the rest of the industry. ZEG outperforms 62.00% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that ZEG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.71, ZEG is in line with its industry, outperforming 44.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 4.92 |
ROIC/WACC1.59
WACC8.84%
2.3 Liquidity
A Current Ratio of 0.90 indicates that ZEG may have some problems paying its short term obligations.
ZEG's Current ratio of 0.90 is on the low side compared to the rest of the industry. ZEG is outperformed by 76.00% of its industry peers.
ZEG has a Quick Ratio of 0.90. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG's Quick ratio of 0.70 is on the low side compared to the rest of the industry. ZEG is outperformed by 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.91%, which is quite good.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 15.48% in the last year.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.35% on average per year.
Based on estimates for the next years, ZEG will show a small growth in Revenue. The Revenue will grow by 6.34% on average per year.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.04 indicates a correct valuation of ZEG.
62.00% of the companies in the same industry are more expensive than ZEG, based on the Price/Earnings ratio.
ZEG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.50.
Based on the Price/Forward Earnings ratio of 13.23, the valuation of ZEG can be described as correct.
64.00% of the companies in the same industry are more expensive than ZEG, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.44. ZEG is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.04 | ||
| Fwd PE | 13.23 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than the industry average as 64.00% of the companies are valued more cheaply.
The rest of the industry has a similar Price/Free Cash Flow ratio as ZEG.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.01 | ||
| EV/EBITDA | 22.78 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.29
PEG (5Y)0.86
EPS Next 2Y12.94%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.31%, ZEG has a reasonable but not impressive dividend return.
ZEG's Dividend Yield is a higher than the industry average which is at 3.00.
Compared to an average S&P500 Dividend Yield of 2.35, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.31% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 63.60% of its income as dividend. This is not a sustainable payout ratio.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
FRA:ZEG (7/17/2025, 7:00:00 PM)
119.65
-0.8 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.88%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap370.97B
Analysts82.86
Price Target158.42 (32.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.31% |
Yearly Dividend2.56
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.34%
Min EPS beat(2)-0.63%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.86%
Min EPS beat(4)-1.9%
Max EPS beat(4)9.32%
EPS beat(8)5
Avg EPS beat(8)2.24%
EPS beat(12)9
Avg EPS beat(12)3.68%
EPS beat(16)11
Avg EPS beat(16)2.44%
Revenue beat(2)1
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)-1.67%
PT rev (3m)-6.75%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)0.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.04 | ||
| Fwd PE | 13.23 | ||
| P/S | 7.81 | ||
| P/FCF | 47.01 | ||
| P/OCF | 32.82 | ||
| P/B | 10.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.78 |
EPS(TTM)7.46
EY6.23%
EPS(NY)9.04
Fwd EY7.56%
FCF(TTM)2.55
FCFY2.13%
OCF(TTM)3.65
OCFY3.05%
SpS15.32
BVpS11.43
TBVpS-4.91
PEG (NY)1.29
PEG (5Y)0.86
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROCE | 17.15% | ||
| ROIC | 14.1% | ||
| ROICexc | 15.14% | ||
| ROICexgc | 76.66% | ||
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% | ||
| FCFM | 16.62% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 58.81% | ||
| Cap/Sales | 7.18% | ||
| Interest Coverage | 9.49 | ||
| Cash Conversion | 65.63% | ||
| Profit Quality | 117.58% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 4.92 |
F-Score9
WACC8.84%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y14.19%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%